Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer

BMC Cancer

Table 5 Univariate and multivariate analysis with recurrence-free survival for cT1 breast cancer

Parameters	Univarite analysis			Multivarite analysis
Parameters	Hazard ratio	95% CI	p value	Hazard ratio	95% CI	p value
Age at operation (years old)
≤ 60 vs > 60	0.607	0.310–1.133	0.119
Tumor size (mm)
≤ 10.0 vs > 10.0	2.732	1.177–7.946	0.017	2.658	1.14–7.739	0.021
Estrogen receptor
Negative vs Positive	1.166	0.549–2.870	0.707
Progesterone receptor
Negative vs Positive	1.509	0.808–2.950	0.200
HER2
Negative vs Positive	0.887	0.214–2.449	0.839
Ki67
≤ 20% vs > 20%	0.798	0.274–1.854	0.626
Intrinsic subtype HRBC
No vs Yes	1.216	0.551–3.213	0.651
Intrinsic subtype HER2BC
No vs Yes	0.536	0.030–2.460	0.494
Intrinsic subtype TNBC
No vs Yes	0.947	0.325–2.201	0.909
Pathological axillary lymph node metastasis
No metastasis vs Metastasis	0.945	0.385–2.002	0.891
Lymph vascular invasion
No vs Yes	1.673	0.888–3.076	0.109
Hyperlipidemia
No vs Yes	0.421	0.126–1.047	0.064	1.014	0.057–4.693	0.989
Multiple medicine types for hyperlipidemia
No vs Yes	–	–	0.294
Statins
Non-user vs User	0.345	0.083–0.951	0.038	0.353	0.045–7.151	0.413
Lipophilic statins
Non-user vs User	0.316	0.018–1.451	0.166
Hydrophilic statins
Non-user vs User	0.402	0.065–1.307	0.147
Fibrate
Non-user vs User	1.9701	0.111–9.059	0.545
Nicotinic acid (tocopherol acetate)
Non-user vs User	–	–	0.345
Sterol absorption inhibitors (ezetimibe)
Non-user vs User	–	–	0.409

HER2 Human epidermal growth factor receptor 2, HRBC Hormone receptor-positive breast cancer (ER+ and/or PgR+), HER2BC Human epidermal growth factor receptor 2-enriched breast cancer (ER-, PgR-, and HER2+), TNBC Triple negative breast cancer (ER-, PgR-, and HER2-), CI Confidence intervals

ISSN: 1471-2407